Skip to content

Charles River Laboratories CRL Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
Revvity logo
RevvityRVTY
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
IQVIA logo
IQVIAIQV
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's preferred stock, shares authorized?
Charles River Laboratories (CRL) reported preferred stock, shares authorized of $20M in Q1 2026.
How has Charles River Laboratories's preferred stock, shares authorized changed year-over-year?
Charles River Laboratories's preferred stock, shares authorized decreased by 0.0% year-over-year, from $20M to $20M.
What is the long-term trend for Charles River Laboratories's preferred stock, shares authorized?
Over 5 years (2020 to 2025), Charles River Laboratories's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $20M to $20M.